CRISPR Therapeutics grants CTO 90,000 stock options and 40,000 restricted stock units

CRSP•2026-11-06

CRISPR Therapeutics granted Chief Technical Officer Sivakesava Sakhamuri 90,000 stock options and 40,000 restricted stock units on November 4, 2026. The options expire on November 4, 2036.

1. Equity awards

CRISPR Therapeutics granted Chief Technical Officer Sivakesava Sakhamuri 90,000 stock options and 40,000 restricted stock units on November 4, 2026. The options expire on November 4, 2036.

Sources

CRISPR Therapeutics grants CTO 90,000 stock options and 40,000 restricted stock units

Sec

CRISPR Therapeutics grants CTO 90,000 stock options and 40,000 restricted stock units

1. Equity awards

Related News

HCA Healthcare COO Jon M. Foster reports disposal of $34.39 million in common shares

Zillow Group presents at RBC Capital Markets technology, internet, media and telecommunications conference

Empery Digital 10% owner Tice P. Brown reports sale of common shares worth $1,193.25

Sources

CRISPR Therapeutics grants CTO 90,000 stock options and 40,000 restricted stock units

YDUQS announces combination with Afya

Table Trac declares quarterly cash dividend of $0.02 a share